|Bid||231.40 x 128000|
|Ask||232.00 x 209400|
|Day's Range||221.20 - 233.00|
|52 Week Range||1.75 - 233.00|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CARMIEL, Israel, Feb. 15, 2018-- Protalix BioTherapeutics, Inc., announced today the final dosing of the last patient in the Company’ s phase II clinical trial evaluating OPRX-106, the Company’ s oral ...
CARMIEL, Israel, Jan. 31, 2018--. Protalix BioTherapeutics, Inc., announced that the U.S. Food and Drug Administration has granted Fast Track designation to pegunigalsidase alfa, or PRX-102, the Company’ ...
CARMIEL, Israel, Jan. 29, 2018-- Protalix BioTherapeutics, Inc., announced today that the Company will participate in the 14 th Annual WORLD Symposium™ 2018 taking place February 5– 8, 2018 at the Manchester ...
Protalix Biotherapeutics Inc (NYSE:PLX) stock is riding a nearly 10% gain this morning after the Israeli biotech firm unleashed positive interim data from its Phase II clinical study in ulcerative colitis (UC). The trial is investigating the company's oral anti-TNF drug OPRX-106, with data set loose from the first 14 patients who have completed the randomized, open label, two-arm study. A total of 24 patients were enrolled and randomized to receive 2 mg or 8 mg of OPRX-106, administered orally, once daily, for 8 weeks. The first 14 patients have completed the study, and four patients are currently in treatment and follow-up. The trial evaluated key efficacy endpoints including clinical response and remission utilizing the Mayo score, as well as safety and pharmacokinetics.
CARMIEL, Israel, Jan. 02, 2018-- Protalix BioTherapeutics, Inc., announced today interim data from the first 14 patients that completed, to date, the Company’ s phase II clinical trial of OPRX-106 in patients ...
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
Protalix Biotherapeutics Inc (NYSE:PLX) shares had already been on a solid 3% bump yesterday and in pre-market trading have gone on to race up another close to 7% amid the news of an exciting victory: the Israeli pharma firm's Fabry disease asset PRX-102 gained favor from the European Commission by granting of an Orphan Drug Designation (ODD). Should this orphan drug designation be maintained when the Fabry disease candidate garners approval for marketing in the European Union (EU), this could translate to an advantage of ten years of market exclusivity for Protalix within the EU. For context, the company has designed its PRX-102 asset, or pegunigalsidase alfa, as a plant cell culture expressed, and a chemically modified version of the recombinant alpha-Galactosidase-A protein, aimed to treat Fabry disease that afflicts one person out of every 40,000.
CARMIEL, Israel, Dec. 27, 2017-- Protalix BioTherapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary ...
CARMIEL, Israel, Nov. 29, 2017-- Protalix BioTherapeutics, Inc., announced today the completion of enrollment in the Company’ s phase II clinical trial evaluating OPRX-106, the Company’ s oral antiTNF ...
Continued to Demonstrate Improvement across all Key Fabry Disease Parameters at 24 Months. Low Incidence of Treatment Induced Anti-Drug Antibodies which Reversed Entirely Following 12 Months of Treatment ...
The Carmiel, Israel-based company said it had a loss of 9 cents per share. The drug developer posted revenue of $7.5 million in the period. The company's shares closed at 73 cents. A year ago, they were ...
Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its financial results for the nine months ended September 30, 2017 and provided a corporate update. Patient enrollment in the Company’s phase III clinical trials, referred to as the Balance, Bridge and Bright studies, is on-going.
The Israeli drug maker said it has entered into Ex-US license and collaboration agreement with Chiesi Farmaceutici S.p.A., or Chiesi, for pegunigalsidase alfa, or PRX-102, the Company’s chemically modified version of the recombinant protein alpha-Galactosidase-A protein that is currently being evaluated in phase III clinical trials for the treatment of Fabry disease. Under the terms of the agreement, Protalix has licensed PRX-102 to Chiesi for all markets outside of the United States, and Protalix will receive an upfront payment of $25 million from Chiesi and additional payments of up to $25 million in development costs, capped at $10 million per year. Protalix is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments, and tiered royalties ranging from 15% to 35% on net sales. Protalix will continue to be the manufacturer of PRX-102 for clinical development purposes and commercial purposes after marketing approvals.
The Carmiel, Israel-based company said it had profit of 6 cents per share. The drug developer posted revenue of $6.4 million in the period. The company's shares closed at 65 cents. A year ago, they were ...